Literature DB >> 2903689

Invasive amebiasis in naturally infected New World and Old World monkeys with and without clinical disease.

P C Beaver1, J L Blanchard, H R Seibold.   

Abstract

Histopathological preparations of cecum and colon from monkeys naturally infected with invasive Entamoeba histolytica were examined to determine the distribution of amebae in the tissues and the types of lesions, if any, associated with them. Infections were studied in 3 New World species (10 Callicebus moloch, 1 C. torquatus, and 2 Aotus trivirgatus) and 3 Old World species (8 Macaca mulatta, 6 Erythrocebus patas, and 1 Cercopithecus aethiops). Amebiasis was recorded as the principal or a contributing cause of death of all of the 13 New World monkeys and in 6 of the 15 Old World monkeys; amebiasis was detected in the rest of the monkeys only after tissues were re-examined specifically for amebae. Amebae causing no apparent damage were found in the lamina propriae, mainly at the muscularis mucosae. Most frequent were colonies or aggregates of amebae in the crypts between the epithelium and basement membrane, causing either no evident necrosis or changes ranging from necrosis and disarrangement of adjacent cells to complete destruction of the epithelium and reduction of the cells to pyknotic bodies. A lesion interpreted as possibly characteristic of carrier-state invasive amebiasis was destruction of the epithelium in patches of mucosal crypts, not leading to ulceration. Uncommon but present in both New and Old World monkeys were typical areas of surface erosion and classical flask-shaped ulcers. The observations show that in some species of Old World monkeys amebiasis can be invasive without causing clinical disease.

Entities:  

Mesh:

Year:  1988        PMID: 2903689     DOI: 10.4269/ajtmh.1988.39.343

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

1.  Entamoeba histolytica and Entamoeba dispar infections in cynomolgus monkeys imported into Japan for research.

Authors:  Jun-ichiro Takano; Toyoko Narita; Hiroshi Tachibana; Toshiyuki Shimizu; Hirofumi Komatsubara; Keiji Terao; Koji Fujimoto
Journal:  Parasitol Res       Date:  2005-07-01       Impact factor: 2.289

2.  Molecular identification of Entamoeba spp. in captive nonhuman primates.

Authors:  B Levecke; Leentje Dreesen; Pierre Dorny; Jaco J Verweij; Francis Vercammen; Stijn Casaert; Jozef Vercruysse; Peter Geldhof
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

3.  Development of RNA Interference Trigger-Mediated Gene Silencing in Entamoeba invadens.

Authors:  Susmitha Suresh; Gretchen Ehrenkaufer; Hanbang Zhang; Upinder Singh
Journal:  Infect Immun       Date:  2016-03-24       Impact factor: 3.441

4.  Expression, purification, and evaluation of recombinant LecA as a candidate for an amebic colitis vaccine.

Authors:  L Barroso; M Abhyankar; Z Noor; K Read; K Pedersen; R White; C Fox; W A Petri; D Lyerly
Journal:  Vaccine       Date:  2013-07-01       Impact factor: 3.641

5.  Comparison of Entamoeba histolytica DNA isolated from a cynomolgus monkey with human isolates.

Authors:  Jun-Ichiro Takano; Toyoko Narita; Hiroshi Tachibana; Keiji Terao; Koji Fujimoto
Journal:  Parasitol Res       Date:  2007-03-15       Impact factor: 2.289

Review 6.  Host-pathogen interaction in amebiasis and progress in vaccine development.

Authors:  C D Huston; W A Petri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

7.  Entamoeba histolytica and E. dispar infections in captive macaques (Macaca fascicularis) in the Philippines.

Authors:  Windell L Rivera; John Anthony D L Yason; Davin Edric V Adao
Journal:  Primates       Date:  2009-10-28       Impact factor: 2.163

8.  Entamoeba histolytica infections in captive primates.

Authors:  Jaco J Verweij; Jan Vermeer; Eric A T Brienen; Coby Blotkamp; Daphne Laeijendecker; Lisette van Lieshout; Anton M Polderman
Journal:  Parasitol Res       Date:  2003-02-07       Impact factor: 2.289

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.